南京赛诺生物团队具有二十年以上国内外头部企业的化合物筛选和开发能力,依托于领先的技术蛋白结构优化平台,聚焦于糖尿病等代谢类生物新药开发,目前开发的GLP-1/GIP/GCGR三靶点化合物,超长效胰岛素,口服GLP-1/amylin双靶点化合物分别进入临床前验证阶段,建立完整的降糖,减肥和NASH筛选平台。司美格鲁肽,胰岛素类似物等开发到临床前和临床研究阶段。同时探索干细胞,小核酸等新型代谢类疾病治疗方法。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows